Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders

American Journal Geriatric Pharmacotherapy

Volumn 8, Issue 4, 2010, Pages 331-373

  Guay, David R P ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HEALTHPARTNERS INSTITUTE   (United States)

Author keywords

benzoquinolizine derivatives; dopamine; movement disorders; norepinephrine; serotonin; tardive disorders; tetrabenazine

Indexed keywords

AMANTADINE; BENZOQUINOLIZINE DERIVATIVE; BROMOCRIPTINE; CARBIDOPA; CLONAZEPAM; CYTOCHROME P450 2D6; DIHYDROTETRABENAZINE; DOPAMINE; FLUMAZENIL; FLUPHENAZINE; LEVODOPA; LITHIUM; METIROSINE; METOCLOPRAMIDE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PAROXETINE; PIMOZIDE; QUINOLIZINE DERIVATIVE; RESERPINE; SEROTONIN; TETRABENAZINE; THIOPROPAZATE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG;

AKATHISIA; AMENORRHEA; ATAXIA; ATHETOSIS; BLEPHAROSPASM; BRADYCARDIA; BRONCHITIS; CHOREA; CHOREOATHETOSIS; CLINICAL TRIAL; CONFUSION; DEPRESSION; DROWSINESS; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPNEA; DYSTONIA; DYSURIA; ECCHYMOSIS; FALLING; FATIGUE; GAIT DISORDER; GENOTYPE; GILLES DE LA TOURETTE SYNDROME; HEMIBALLISM; HEMIDYSTONIA; HUMAN; HUNTINGTON CHOREA; HYPERHIDROSIS; HYPERKINESIA; INSOMNIA; KERNICTERUS; LACERATION; LESCH NYHAN SYNDROME; MOTOR DYSFUNCTION; MYALGIA; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PHOTOPHOBIA; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SEDATION; SIDE EFFECT; SUICIDAL BEHAVIOR; TARDIVE DYSKINESIA; TIC; TORSION DYSTONIA; TORTICOLLIS; TREMOR; UPPER RESPIRATORY TRACT INFECTION;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP2D6; DEPRESSION; DOPAMINE; DRUG INTERACTIONS; GENOTYPE; HUMANS; HUNTINGTON DISEASE; HYPERKINESIS; MIDDLE AGED; MOVEMENT DISORDERS; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE, SECONDARY; QUINOLIZINES; RESERPINE; SEROTONIN; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS; YOUNG ADULT;

EID: 77957262796     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2010.08.006     Document Type: Review

References (110)

1. Tetrabenazine (Xenazine) for Huntington's chorea Med Lett Drugs Ther 51 2009 7 8
2. O Lingjaerde Tetrabenazine (Nitoman) in the treatment of psychoses. With a discussion on the central mode of action of tetrabenazine and reserpine Acta Psychiatr Scand 39 Suppl 170 1963 1 109
3. Tetrabenazine (Xenazine tablets) [package insert] May 2008 Biovail Corporation Mississauga, Canada
4. A Pletscher, A Brossi, and KF Gey Benzoquinolizine derivatives: A new class of monoamine decreasing drugs with psychotropic action Int Rev Neurobiol 4 1962 275 306
5. JP Henry, and D Scherman Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles Biochem Pharmacol 38 1989 2395 2404
6. D Peter, T Vu, and RH Edwards Chimeric vesicular monoamine transporters identify structural domains that influence substrate affinity and sensitivity to tetrabenazine JBiol Chem 271 1996 2979 2986
7. AM Gonzalez, D Walther, A Pazos, and GR Uhl Synaptic vesicular monoamine transporter expression: Distribution and pharmacologic profile Brain Res Mol Brain Res 22 1994 219 226
8. DL McLellan, RJ Chalmers, and RH Johnson A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea Lancet 1 1974 104 107
9. SJ Pearson, and GP Reynolds Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease Neuropharmacology 27 1988 717 719
10. W Stumpf, EH Graul, and H Hundeshagen Experimentelle Untersuchungen zur Pharmakologie des mit 3H-markierten tetra-benazines Arzneim Forsch 11 1961 47 49
11. MR Kilbourn, JN DaSilva, and KA Frey In vivo imaging of vesicular monoamine transporters in human brain using [11C]tetrabenazine and positron emission tomography J Neurochem 60 1993 2315 2318
12. US Food and Drug Administration, Center for Drug Evaluation and Research. New Drug Application No. 21-894: Tetrabenazine. Medical and Clinical Pharmacology reviews.
13. R Mehvar, F Jamali, MW Watson, and D Skelton Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies Drug Metab Dispos 15 1987 250 255
14. MS Roberts, S McLean, KS Millingen, and HM Galloway The pharmacokinetics of tetrabenazine and its hydroxyl metabolite in patients treated for involuntary movement disorders Eur J Clin Pharmacol 29 1986 703 708
15. DE Schwartz, H Bruderer, J Rieder, and A Brossi Metabolic studies of tetrabenazine, a psychotropic drug in animals and man Biochem Pharmacol 15 1966 645 655
16. MR Kilbourn, LC Lee, MJ Heeg, and DM Jewett Absolute configuration of (+)-alpha-dihydrotetrabenazine, an active metabolite of tetrabenazine Chirality 9 1997 59 62
17. A Reches, MN Hassan, VR Jackson, and S Fahn Lithium attenuates dopamine depleting effects of reserpine and tetrabenazine but not that of alpha methyl-p-tyrosine Life Sci 33 1983 157 160
18. T Furukawa, I Ushizima, and N Ono Modifications by lithium of behavioral responses to methamphetamine and tetrabenazine Psychopharmacologia 42 1975 243 248
19. A Malik, and V Balkoski Neurotransmitter depleter tetrabenazine; potential candidate for schizophrenia treatment? Schizophr Res 96 2007 267 268
20. J Pearce Reversal of hemiballismus by tetrabenazine JAMA 219 1972 1345 Letter
21. D Riley, and AE Lang Hemiballism in multiple sclerosis Mov Disord 3 1988 88 94
22. JF Mart-Mass, and JA Obeso Coprolalia associated with hemiballismus: Response to tetrabenazine Clin Neuropharmacol 8 1985 189 190
23. MF Geoghegan, CH Khaw, and PA McCormick Hemiballismus Ir Med J 95 2002 123 124
24. RB Dewey Jr, and J Jankovic Hemiballism-hemichorea Clinical and pharmacologic findings in 21 patients Arch Neurol 46 1989 862 867
25. RW Laing, and SJ Howell Acute bilateral ballism in a patient with intravascular dissemination of gastric carcinoma Neuropathol Appl Neurobiol 18 1992 201 205
26. O Sitburana, and WG Ondo Tetrabenazine for hyperglycemic-induced hemichorea-hemiballismus Mov Disord 21 2006 2023 2025
27. P Shanahan, M Hutchinson, and A Bohan Hemichorea, moya-moya, and ulcerative colitis Mov Disord 16 2001 570 572
28. E Brandrup Tetrabenacine treatment in persisting dyskinesia caused by psychopharmaca Am J Psychiatry 118 1961 551 552
29. WA MacCallum Tetrabenazine for extra-pyramidal movement disorders Br Med J 1 1970 760
30. K Srinivasan, KS Mouli, and B Viegas Metoclopramide induced tardive dyskinesia J Indian Med Assoc 89 1991 260 261
31. A Fve, B Angelard, and J Lacau St Guily Laryngeal tardive dyskinesia J Neurol 242 1995 455 459
32. HJ Koch, A Szecsey, M Vogel, and D Fischer-Barnicol Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapine and tiapride Int J Clin Pract 57 2003 147 149
33. M Stacy, and J Jankovic Tardive tremor Mov Disord 7 1992 53 57
34. E Storey, and J Lloyd Tardive tremor Mov Disord 12 1997 808 810
35. SK Singh, and J Jankovic Tardive dystonia in patients with Tourette's syndrome Mov Disord 3 1988 274 280
36. B Rauchverger, V Isakov, and M Jabarin Olanzapine-induced tardive dystonia successfully treated by tetrabenazine J Neuropsychiatry Clin Neurosci 19 2007 484 485
37. M Kalian, V Lerner, and M Goldman Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propranolol and clozapine with tetrabenazine J Nerv Ment Dis 181 1993 649 651
38. PM FitzGerald, and J Jankovic Tardive oculogyric crises Neurology 39 1989 1434 1437
39. CO Soutar Tetrabenazine for Huntington's chorea Br Med J 4 1970 55
40. MM Hoehn, and M Cherington Spinal myoclonus Neurology 27 1977 942 946
41. J Jankovic, and R Pardo Segmental myoclonus. Clinical and pharmacologic study Arch Neurol 43 1986 1025 1031
42. CH Hawkes, and CH Nourse Tetrabenazine in Sydenham's chorea Br Med J 1 1977 1391 1392
43. CJ Vecht, JD Meerwaldt, and AJ Lees What is it? Case 2, 1991: Unusual tremor, myoclonus, and a limping gait Mov Disord 6 1991 371 375
44. G Linazasoro, M Urtasun, and JJ Poza Generalized chorea induced by nonketotic hyperglycemia Mov Disord 8 1993 119 120
45. S Papapetropoulos, and C Singer Management of the extrapyramidal syndrome in chronic acquired hepatocerebral degeneration (CAHD) Mov Disord 20 2005 1088 1089
46. A Lagueny, P Burbaud, and G Le Masson Involvement of respiratory muscles in adult-onset dystonia: A clinical and electrophysiological study Mov Disord 10 1995 708 713
47. P Vieregge Tetrabenazine in the treatment of senile vocal tics J Neurol 235 1987 126 127
48. A Alentorn, A Palasi, and J Campdelacreu Pelvic dyskinesia with an outstanding response to tetrabenazine Prog Neuropsychopharmacol Biol Psychiatry 33 2009 847 848
49. S Papapetropoulos, and C Singer Eating dysfunction associated with oromandibular dystonia: Clinical characteristics and treatment considerations Head Face Med 2 2006 47
50. H Pakkenberg The effect of tetrabenazine in some hyperkinetic syndromes Acta Neurol Scand 44 1968 391 393
51. MA Dalby Effect of tetrabenazine on extrapyramidal movement disorders Br Med J 2 1969 422 423
52. KJ Astin, and EW Gumpert Letter: Tetrabenazine in chorea Lancet 1 1974 512
53. D Kingston Tetrabenazine for involuntary movement disorders Med J Aust 1 1979 628 630
54. J Jankovic, and J Ford Blepharospasm and orofacial-cervical dystonia: Clinical and pharmacological findings in 100 patients Ann Neurol 13 1983 402 411
55. S Fahn A therapeutic approach to tardive dyskinesia J Clin Psychiatry 46 1985 19 24
56. MW Watson, D Skelton, and F Jamali Treatment of tardive dyskinesia: Preliminary report on use of tetrabenazine Can J Psychiatry 33 1988 11 13
57. J Jankovic, and J Beach Long-term effects of tetrabenazine in hyperkinetic movement disorders Neurology 48 1997 358 362
58. D Paleacu, N Giladi, and O Moore Tetrabenazine treatment in movement disorders Clin Neuropharmacol 27 2004 230 233
59. C Kenney, C Hunter, and J Jankovic Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders Mov Disord 22 2007 193 197 (Pubitemid 46374760)
60. R Fog, and H Pakkenberg Combined nitoman-pimozide treatment of Huntington's chorea and other hyperkinetic syndromes Acta Neurol Scand 46 1970 249 251
61. M Swash, AH Roberts, H Zakko, and KW Heathfield Treatment of involuntary movement disorders with tetrabenazine J Neurol Neurosurg Psychiatry 35 1972 186 191
62. DL McLellan The suppression of involuntary movements with tetrabenazine Scott Med J 17 1972 367 370
63. H Kazamatsuri, C Chien, and JO Cole Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine Arch Gen Psychiatry 27 1972 95 99
64. H Pakkenberg, and R Fog Spontaneous oral dyskinesia. Results of treatment with tetrabenazine, pimozide, or both Arch Neurol 31 1974 352 353
65. RD Sweet, R Bruun, E Shapiro, and AK Shapiro Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine Arch Gen Psychiatry 31 1974 857 861
66. AW McArthur, M Pollock, and NA Smidt Combined therapy with tetrabenazine and pimozide in Huntington's chorea: Pilot study N Z Med J 83 1976 114 116
67. CY Huang, JG McLeod, RT Holland, and C Elliot tetrabenazine in the treatment of Huntington's chorea Med J Aust 1 1976 583 584
68. JU Toglia, M McGlamery, and RR Sambandham tetrabenazine in the treatment of Huntington's chorea and other hyperkinetic movement disorders J Clin Psychiatry 39 1978 81 87
69. AE Lang, and CD Marsden Alpha methylparatyrosine and tetrabenazine in movement disorders Clin Neuropharmacol 5 1982 375 387
70. J Jankovic, DG Glaze, and JD Frost Jr Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome Neurology 34 1984 688 692
71. S Fahn Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents Adv Neurol 37 1983 267 276
72. CD Marsden, MH Marion, and N Quinn The treatment of severe dystonia in children and adults J Neurol Neurosurg Psychiatry 47 1984 1166 1173
73. M Bartels, and E Zeller Tetrabenazine (Nitoman) therapy of chronic spontaneous oral dyskinesia. A video- and EMG-controlled study Eur Arch Psychiatry Neurol Sci 234 1984 172 174
74. UJ Kang, RE Burke, and S Fahn Natural history and treatment of tardive dystonia Mov Disord 1 1986 193 208
75. UJ Kang, RE Burke, and S Fahn Tardive dystonia Adv Neurol 50 1988 415 429
76. J Jankovic, and J Orman Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias Neurology 38 1988 391 394
77. J Jankovic, TC Caskey, JT Stout, and IJ Butler Lesch-Nyhan syndrome: A study of motor behavior and cerebrospinal fluid neurotransmitters Ann Neurol 23 1988 466 469
78. M Stacy, F Cardoso, and J Jankovic Tardive stereotypy and other movement disorders in tardive dyskinesias Neurology 43 1993 937 941
79. WG Ondo, PA Hanna, and J Jankovic Tetrabenazine treatment for tardive dyskinesia: Assessment by randomized videotape protocol Am J Psychiatry 156 1999 1279 1281
80. WG Ondo, R Tintner, M Thomas, and J Jankovic Tetrabenazine treatment for Huntington's disease-associated chorea Clin Neuropharmacol 25 2002 300 302
81. C Kenney, C Hunter, A Davidson, and J Jankovic Shortterm effects of tetrabenazine on chorea associated with Huntington's disease Mov Disord 22 2007 10 13
82. M Porta, M Sassi, and M Cavallazzi Tourette's syndrome and role of tetrabenazine: Review and personal experience Clin Drug Investig 28 2008 443 459
83. A Fasano, F Cadeddu, and A Guidubaldi The longterm effect of tetrabenazine in the management of Huntington disease Clin Neuropharmacol 31 2008 313 318
84. S Frank Huntington Study Group/TETRA-HD Investigators Tetrabenazine as anti-chorea therapy in Huntington disease: An open-label continuation study BMC Neurol 9 2009 62
85. RB Godwin-Austen, and T Clark Persistent phenothiazine dyskinesia treated with tetrabenazine Br Med J 4 1971 25 26
86. BS Gilligan, J Wodak, JL Veale, and OR Munro tetrabenazine in the treatment of extrapyramidal dyskinesias Med J Aust 2 1972 1054 1056
87. SW Asher, and MJ Aminoff Tetrabenazine and movement disorders Neurology 31 1981 1051 1054
88. J Jankovic Treatment of hyperkinetic movement disorders with tetrabenazine: A double-blind crossover study Ann Neurol 11 1982 41 47
89. J Jankovic Tetrabenazine in the treatment of hyperkinetic movement disorders Adv Neurol 37 1983 277 289
90. L Brusa, A Orlacchio, and V Moschella Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine Mov Disord 24 2009 126 129
91. H Kazamatsuri, CP Chien, and JO Cole Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine Am J Psychiatry 130 1973 479 483
92. Huntington Study Group Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial Neurology 66 2006 366 372
93. S Frank, W Ondo, and S Fahn A study of chorea after tetrabenazine withdrawal in patients with Huntington disease Clin Neuropharmacol 31 2008 127 133
94. C Kenney, C Hunter, A Mejia, and J Jankovic Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol 29 2006 259 264
95. N Giladi, and E Melamed Levodopa therapy can ameliorate tetrabenazine-induced parkinsonism Mov Disord 14 1999 158 159
96. MJ Novak, and SJ Tabrizi Huntington's disease BMJ 340 2010 C3109
97. AZ Ables, and R Nagubilli Prevention, recognition, and management of serotonin syndrome Am Fam Physician 81 2010 1139 1142
98. GM Petzinger, and SB Bressman A case of tetrabenazineinduced neuroleptic malignant syndrome after prolonged treatment Mov Disord 12 1997 246 248
99. M Ossemann, CJ Sindic, and C Laterre Tetrabenazine as a cause of neuroleptic malignant syndrome Mov Disord 11 1996 95
100. J Kulisevsky, M Lima de Freitas, and L Barraquer-Bordas Bilateral akinesia in drug-induced parkinsonism after a subthalamic lesion Mov Disord 9 1994 111 112
101. D Mateo, JL Muoz-Blanco, and S Gimnez-Roldn Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease Clin Neuropharmacol 15 1992 63 68
102. JH Moss, and DE Stewart Iatrogenic parkinsonism in Huntington's chorea Can J Psychiatry 31 1986 865 866
103. RE Burke, S Fahn, and R Mayeux et al Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease Neurology 31 1981 1022 1025
104. MA Bruneau, P Lesprance, and S Chouinard Catastrophic reactions induced by tetrabenazine Can J Psychiatry 47 2002 683
105. W Schreiber, JC Krieg, and T Eichhorn Reversal of tetrabenazine induced depression by selective noradrenaline (norepinephrine) reuptake inhibition J Neurol Neurosurg Psychiatry 67 1999 550
106. E Stevens, A Roman, and M Houa Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia Intensive Care Med 24 1998 369 371
107. RE Burke, A Reches, and MM Traub Tetrabenazine induces acute dystonic reactions Ann Neurol 17 1985 200 202
108. BO Mikkelsen Tolerance of tetrabenazine during long-term treatment Acta Neurol Scand 68 1983 57 60
109. T Mestre, J Ferreira, and MM Coelho Therapeutic interventions for symptomatic treatment in Huntington's disease Cochrane Database Syst Rev 3 2009 CD006456
110. J Jankovic Treatment of hyperkinetic movement disorders Lancet Neurol 8 2009 844 856